Biogen's lead balloon

How Biogen's stock has fared since the launch of aducanumab Phase III AD trials

Biogen took a 29% haircut to $226.88 on Thursday following its decision to discontinue the Phase III ENGAGE and EMERGE trials of aducanumab for Alzheimer’s disease. The company's stock price has been dragged down 48% from a high of $476 in March 2015, when it announced detailed data from the

Read the full 505 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE